Otic Pharma

Foam-based Products for the Treatment of Ear, Nose, and Throat Disorders

Health Tech & Life Sciences
Acquired by Novus Therapeutics
Acquired Rehovot, Israel Founded 2008
LinkedIn
Last updated 2026-06-18
Total raised
$5.2M
Last: 2015-05
Stage
Acquired
Founded
2008
Headcount
1-10
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences

About

Otic Pharma Ltd develops therapeutic products for ear, nose, and throat (ENT) disorders. The companys leading investigational drug, FoamOtic Externa, which is currently being prepared for a Phase III clinical trial, is a foam-based version of the industrys most commonly used, non-ototoxic antibiotic, ciprofloxacin. Based on the companys proprietary FoamOtic platform, FoamOtic Externa enables sustained drug exposure, fewer administrations, and lower doses for treatment of acute otitis externa (AOE, or "swimmer's ear"). This steroid-free product is easy to apply, with no need to tilt the head or lie on one's side to ensure that the medication remains in the ear. This makes administration more convenient, especially for children, and thus can improve compliance and safety. Other pipeline products based on the FoamOtic platform in development include FoamOtic Sinus for chronic sinusitis, Foam-O-Vet for otitis externa in dogs, and FoamOtic Media for the treatment of otitis media.

Funding history · 4 rounds · $5.2M total

2015-05
2012-02
$4.3M
2009-06
Date unknown
$650K

Q&A

What is Otic Pharma's primary focus?
Otic Pharma develops therapeutic products for ear, nose, and throat (ENT) disorders, utilizing a proprietary FoamOtic platform.
What is Otic Pharma's leading investigational drug?
Otic Pharma's leading investigational drug is FoamOtic Externa, a foam-based version of ciprofloxacin, which is being prepared for a Phase III clinical trial for acute otitis externa (AOE, or "swimmer's ear").
What are some other pipeline products based on Otic Pharma's FoamOtic platform?
Other pipeline products based on the FoamOtic platform include FoamOtic Sinus for chronic sinusitis, Foam-O-Vet for otitis externa in dogs, and FoamOtic Media for the treatment of otitis media.
When was Otic Pharma founded?
Otic Pharma was founded in January 2008.
How many employees does Otic Pharma have?
Otic Pharma has 1-10 employees.
What is Otic Pharma's total funding raised?
Otic Pharma has raised a total of $5,246,000 USD.
Which investors participated in Otic Pharma's June 2009 funding round?
Peregrine Ventures participated in Otic Pharma's funding round in June 2009.
Which investor participated in Otic Pharma's February 2012 funding round?
OrbiMed participated in Otic Pharma's funding round in February 2012.
Which investors participated in Otic Pharma's May 2015 funding round?
OrbiMed and Pontifax participated in Otic Pharma's funding round in May 2015.
What is Otic Pharma's current status?
Otic Pharma is currently active, but was acquired by Novus Therapeutics in May 2017.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 PatentsVerified

Tags

chronic-diseasepharmaceuticalsdrug-deliverypharma-companiespetstreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

LinkedInlinkedin.com/company/6973010

Identifiers & details

Founded2008-1
OfficesIrvine
Status reasonAcquired (Inactive) by Novus Therapeutics on May 2017 - closed due to acquisition

Acquisitions & public offerings

Acquired by Novus Therapeutics 2017-05

Radar intelligence

Patents

EPO9